Cyclin E1 expression and malignancy in meningiomas

Autor(es)

Araujo Pereira, Benedito Jamilson ^[1] ; de Santana Junior, Pedro Augustto ^[1] ; de Almeida, Antonio Nogueira ^[2] ; Cavalcante, Stella Goncalves ^[1] ; Martins de Melo, Keyde Cristina ^[1] ; Pires de Aguiar, Paulo Henrique ^[2] ; Paiva, Wellingson da Silva ^[2] ; Oba-Shinjo, Sueli Mieko ^[1] ; Nagahashi Marie, Suely Kazue ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Med FMUSP, Dept Neurol, Lab Biol Mol & Celular LIM 15, Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Hosp Clin, Div Neurocirurgia Func IPQ, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: CLINICAL NEUROLOGY AND NEUROSURGERY; v. 190, MAR 2020.
• Citações Web of Science: 0

Resumo

Objective: The aim of the present study was to analyze if the pathway Skp2-p27-cyclin El could also be a tumor progression marker for meningiomas. Patients and methods: We used quantitative real-time PCR to assess the relative expression levels of the genes coding for cyclin El (CCNE1), Skp2 (SKP2), and p27 (P27). The expression levels were compared in grades Ito III meningiomas and among different histological subtypes of grade I meningiomas. Results: Anaplastic meningiomas accounted for 4.9%, atypical meningiomas for 23.5% and grade I meningiomas for 71.6%.CCNE1 expression level was significantly higher in grade II compared to grade I meningiomas (p = 0.0027), and its expression level reliably predicts grade II meningiomas (ROC AUC = 0.731, p = 0.003). CCNE1 expression also correlated with SKP2 and P27 expression levels in grade I meningiomas (r = 0.539, p < 0.0001 and r = 0.687, p = < 0.0001, respectively for CCNE1/SKP2 and CCNE1/P27, Spearman's test). Fibrous subtype among grade I meningiomas presented the highest expression levels of CCNE1, SKP2 and P27. Higher expression of cyclin El protein was detected in the nuclei of atypical meningiomas compared to grade I meningiomas. Conclusions: CCNE1 expression level predicts meningioma malignancy, and the fibrous subtype presents the highest gene expression levels among grade I meningiomas. (AU)

• Processo FAPESP: 14/50137-5 - Caracterização molecular de doenças monogênicas do desenvolvimento por sequenciamento em larga escala
• Beneficiário: Berenice Bilharinho de Mendonça
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 01/12898-4 - Genoma clínico
• Beneficiário: Suely Kazue Nagahashi Marie
• Modalidade de apoio: Auxílio à Pesquisa - Programa GENOMA
• Processo FAPESP: 04/12133-6 - Procura de marcadores moleculares relacionados ao diagnóstico e prognóstico de tumores do sistema nervoso central
• Beneficiário: Suely Kazue Nagahashi Marie
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 13/02162-8 - Patogênese molecular e caracterização de doenças monogênicas do desenvolvimento: um caminho para a medicina translacional
• Beneficiário: Berenice Bilharinho de Mendonça
• Modalidade de apoio: Auxílio à Pesquisa - Temático